Product NDC: | 67457-239 |
Proprietary Name: | Octreotide Acetate |
Non Proprietary Name: | octreotide acetate |
Active Ingredient(s): | 50 ug/mL & nbsp; octreotide acetate |
Administration Route(s): | INTRAVENOUS; SUBCUTANEOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 67457-239 |
Labeler Name: | Mylan Institutional LLC |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA079198 |
Marketing Category: | ANDA |
Start Marketing Date: | 20130425 |
Package NDC: | 67457-239-01 |
Package Description: | 10 SYRINGE in 1 CARTON (67457-239-01) > 1 mL in 1 SYRINGE (67457-239-00) |
NDC Code | 67457-239-01 |
Proprietary Name | Octreotide Acetate |
Package Description | 10 SYRINGE in 1 CARTON (67457-239-01) > 1 mL in 1 SYRINGE (67457-239-00) |
Product NDC | 67457-239 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | octreotide acetate |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS; SUBCUTANEOUS |
Start Marketing Date | 20130425 |
Marketing Category Name | ANDA |
Labeler Name | Mylan Institutional LLC |
Substance Name | OCTREOTIDE ACETATE |
Strength Number | 50 |
Strength Unit | ug/mL |
Pharmaceutical Classes | Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA] |